Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ES-SCLC patients. The safety profile was manageable, with severe ...
Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback